Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
B Liu, M Li, Z Zhou, X Guan, Y **ang - Journal of autoimmunity, 2020 - Elsevier
The emergent outbreak of coronavirus disease 2019 (COVID-19) has caused a global
pandemic. Acute respiratory distress syndrome (ARDS) and multiorgan dysfunction are …
pandemic. Acute respiratory distress syndrome (ARDS) and multiorgan dysfunction are …
Acute graft-versus-host disease—biologic process, prevention, and therapy
When T cells from a bone marrow donor begin to attack the host within 3 months after
hematopoietic-cell transplantation, acute graft-versus-host disease results. The disease …
hematopoietic-cell transplantation, acute graft-versus-host disease results. The disease …
Pathophysiology of chronic graft-versus-host disease and therapeutic targets
Chronic GVHD, an autoimmune disease that follows allogeneic hematopoietic-cell
transplantation, is characterized by infections and debilitating tissue injury leading to …
transplantation, is characterized by infections and debilitating tissue injury leading to …
[HTML][HTML] IL-6 pathway in the liver: from physiopathology to therapy
Summary Interleukin 6 (IL-6) is a pleiotropic four-helix-bundle cytokine that exerts multiple
functions in the body. In the liver, IL-6 is an important inducer of the acute phase response …
functions in the body. In the liver, IL-6 is an important inducer of the acute phase response …
How COVID-19 induces cytokine storm with high mortality
S Hojyo, M Uchida, K Tanaka, R Hasebe… - Inflammation and …, 2020 - Springer
The newly emerging coronavirus disease 2019 (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China, but …
respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China, but …
[HTML][HTML] The biology of chronic graft-versus-host disease: a task force report from the National Institutes of Health Consensus Development Project on Criteria for …
Chronic graft-versus-host disease (GVHD) is the leading cause of late, nonrelapse mortality
and disability in allogeneic hematopoietic cell transplantation recipients and a major …
and disability in allogeneic hematopoietic cell transplantation recipients and a major …
Current concepts and advances in graft-versus-host disease immunology
Worldwide, each year over 30,000 patients undergo an allogeneic hema-topoietic stem cell
transplantation with the intent to cure high-risk hematologic malignancy, immunodeficiency …
transplantation with the intent to cure high-risk hematologic malignancy, immunodeficiency …
Chronic graft-versus-host disease: biological insights from preclinical and clinical studies
KPA MacDonald, GR Hill… - Blood, The Journal of the …, 2017 - ashpublications.org
With the increasing use of mismatched, unrelated, and granulocyte colony-stimulating factor–
mobilized peripheral blood stem cell donor grafts and successful treatment of older …
mobilized peripheral blood stem cell donor grafts and successful treatment of older …
Interleukin-6, a cytokine critical to mediation of inflammation, autoimmunity and allograft rejection: therapeutic implications of IL-6 receptor blockade
SC Jordan, J Choi, I Kim, G Wu, M Toyoda, B Shin… - …, 2017 - journals.lww.com
The success of kidney transplants is limited by the lack of robust improvements in long-term
survival. It is now recognized that alloimmune responses are responsible for the majority of …
survival. It is now recognized that alloimmune responses are responsible for the majority of …
[HTML][HTML] MHC class II antigen presentation by the intestinal epithelium initiates graft-versus-host disease and is influenced by the microbiota
Graft-versus-host disease (GVHD) in the gastrointestinal (GI) tract is the principal
determinant of lethality following allogeneic bone marrow transplantation (BMT). Here, we …
determinant of lethality following allogeneic bone marrow transplantation (BMT). Here, we …